Key result
High-sensitivity cardiac troponin (hs-cTn) screening identifies patients at high risk of heart failure, but specific clinical trials are needed to demonstrate its efficacy in the general population.
Why the study?
Does cardiovascular risk evaluation using high-sensitivity cardiac troponin assays identify individuals in the general population at higher risk for heart failure progression?
Population
General population
Design
Review
Authors
Loading...
Troponin-based screening may aid early risk stratification in primary care; hypothesis-generating for outcome trials before practice change.
Does cardiovascular risk evaluation using high-sensitivity cardiac troponin assays identify individuals in the general population at higher risk for heart failure progression?
High-sensitivity cardiac troponin assays show promise for screening the general population to identify individuals at high risk for heart failure, warranting future clinical trials.
Clerico et al. (2020) conducted a review in Cardiovascular risk. High-sensitivity cardiac troponin (hs-cTn) screening was evaluated. High-sensitivity cardiac troponin (hs-cTn) screening identifies patients at high risk of heart failure, but specific clinical trials are needed to demonstrate its efficacy in the general population.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: